X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1927) 1927
Book Review (740) 740
Publication (165) 165
Conference Proceeding (21) 21
Book Chapter (19) 19
Transcript (2) 2
Book / eBook (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1526) 1526
humans (1404) 1404
oncology (854) 854
hematology (714) 714
multiple myeloma (689) 689
male (603) 603
bortezomib (578) 578
female (569) 569
refractory multiple-myeloma (544) 544
middle aged (522) 522
multiple myeloma - drug therapy (520) 520
aged (497) 497
cancer (396) 396
adult (370) 370
dexamethasone (326) 326
antineoplastic agents - therapeutic use (310) 310
treatment outcome (310) 310
therapy (306) 306
antineoplastic combined chemotherapy protocols - therapeutic use (294) 294
thalidomide (283) 283
chemotherapy (281) 281
lenalidomide (273) 273
care and treatment (271) 271
refractory myeloma (271) 271
animals (264) 264
pharmacology & pharmacy (255) 255
thalidomide - analogs & derivatives (207) 207
refractory (196) 196
stem-cell transplantation (186) 186
aged, 80 and over (183) 183
transplantation (179) 179
research (177) 177
thalidomide - therapeutic use (172) 172
survival (171) 171
recurrence (168) 168
clinical trials as topic (164) 164
multiple myeloma - pathology (161) 161
drug therapy (154) 154
antineoplastic agents - pharmacology (153) 153
dexamethasone - administration & dosage (153) 153
antineoplastic agents - adverse effects (152) 152
clinical trials (149) 149
neoplasms - drug therapy (148) 148
boronic acids - therapeutic use (147) 147
thalidomide - administration & dosage (147) 147
pyrazines - therapeutic use (146) 146
medicine & public health (145) 145
apoptosis (142) 142
health aspects (140) 140
relapsed (140) 140
combination (138) 138
phase-ii trial (135) 135
prognosis (135) 135
multiple-myeloma (134) 134
antineoplastic combined chemotherapy protocols - adverse effects (129) 129
proteasome inhibitors (127) 127
boronic acids - administration & dosage (126) 126
hematology, oncology and palliative medicine (125) 125
thalidomide - adverse effects (125) 125
pyrazines - administration & dosage (124) 124
non-hodgkins-lymphoma (122) 122
lenalidomide plus dexamethasone (118) 118
analysis (116) 116
chronic lymphocytic-leukemia (116) 116
immunology (114) 114
multiple myeloma - mortality (114) 114
patients (114) 114
leukemia (113) 113
myeloma (113) 113
dose-response relationship, drug (112) 112
phase-ii (109) 109
retrospective studies (108) 108
stem cells (108) 108
abridged index medicus (106) 106
boronic acids - adverse effects (105) 105
pyrazines - adverse effects (104) 104
disease-free survival (100) 100
medical research (100) 100
multiple myeloma - therapy (100) 100
trial (100) 100
phase-2 (98) 98
relapse (98) 98
survival analysis (97) 97
antineoplastic agents - administration & dosage (95) 95
drug resistance, neoplasm (95) 95
lymphomas (95) 95
open-label (95) 95
nf-kappa-b (94) 94
carfilzomib (93) 93
dosage and administration (93) 93
tumors (93) 93
combination therapy (92) 92
review (92) 92
plus dexamethasone (91) 91
article (90) 90
melphalan (90) 90
acute myeloid-leukemia (88) 88
drug administration schedule (87) 87
proteasome inhibitor (87) 87
refractory prostate-cancer (86) 86
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1901) 1901
French (15) 15
Russian (9) 9
German (7) 7
Japanese (5) 5
Polish (5) 5
Spanish (5) 5
Chinese (1) 1
Italian (1) 1
Persian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2005, Volume 352, Issue 24, pp. 2487 - 2498
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 11/2018, Volume 105, Issue 11, pp. 985 - 991
Daratumumab is a monoclonal antibody that targets CD38. It has an anti-tumor action on the myeloma cell and an immunomodulatory action. For relapsing and/or... 
Daratumumab | Multiple myeloma | Monoclonal antibody | Relapsed or refractory
Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 08/2019, Volume 322, Issue 5, pp. 393 - 393
The FDA granted accelerated approval to the nuclear transport inhibitor selinexor in combination with the corticosteroid dexamethasone for patients with... 
MEDICINE, GENERAL & INTERNAL | Disease resistance | Refractory materials | Regulatory agencies | Dexamethasone | Immunomodulation | Medical treatment | CD38 antigen | Multiple myeloma | Monoclonal antibodies | Nuclear transport | Proteasome inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
BULLETIN DU CANCER, ISSN 0007-4551, 09/2017, Volume 104, Issue 9, pp. 707 - 713
Pomalidomide is a second-generation immunomodulatory drug (IMID). Its efficiency overtakes its predecessors' (thalidomide, lenalidomide), with less toxicity.... 
MECHANISM | EFFICACY | SAFETY | Multiple myeloma | PHASE-2 | BORTEZOMIB | Relapsed or refractory | TRIAL | ONCOLOGY | REFRACTORY MYELOMA | LENALIDOMIDE | Pomalidomide | IMID | LOW-DOSE DEXAMETHASONE
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 09/2017, Volume 104, Issue 9, pp. 707 - 713
Pomalidomide is a second-generation immunomodulatory drug (IMID). Its efficiency overtakes its predecessors’ (thalidomide, lenalidomide), with less toxicity.... 
Multiple myeloma | Pomalidomide | IMID | Relapsed or refractory
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1551 - 1560
Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs.... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | RISK | MULTICENTER | THERAPY | ELOTUZUMAB | Drug Administration Schedule | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Spain | Canada | Disease-Free Survival | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Drugs | Medical colleges | Biological products | Multiple myeloma | Monoclonal antibodies | Product development | Lymphomas | Drug therapy | Care and treatment | Analysis | Studies | Protease inhibitors | Hematology | Stem cells | Cytotoxicity | Patients | Drug dosages | Slopes | Therapy | Schedules | Intravenous administration | Stem cell transplantation | Transplantation | Drug screening | Immunosuppressive agents | Randomization | CD38 antigen | Autografts | Anemia | Immunomodulation | Research & development--R&D | FDA approval | Survival | Proteasome inhibitors | Asthma | Refractory materials | Inhibitors | Interactive systems | Response rates | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Gene, ISSN 0378-1119, 02/2018, Volume 644, pp. 80 - 86
A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk... 
Drug response prediction | High-risk | Multiple myeloma | CONSENSUS | BORTEZOMIB | THALIDOMIDE | WORKING GROUP | THERAPY | GENES | GENETICS & HEREDITY | REFRACTORY MYELOMA | STEM-CELL TRANSPLANTATION | EXPRESSION SIGNATURE | STRATIFICATION | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 06/2013, Volume 121, Issue 23, pp. 4647 - 4654
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2009, Volume 27, Issue 21, pp. 3518 - 3525
Journal Article